SERMO’s FICO score for drugs; First of its kind clinical decision tool now includes 600,000 ratings
SERMO, a global social network for physicians has announced major growth in physician ratings of pharmaceutical drugs on its one-of-a-kind Drug Ratings platform. With 625,000 individual ratings across several criteria submitted exclusively by physicians as of March 2018, Drug Ratings is the largest unbiased, global database of physician feedback on drugs.
Launched in May 2017, Drug Ratings is the only global peer-to-peer prescription drug review system sourced exclusively from verified licensed physicians. Drug Ratings gives physicians the ability to research, rate, and share their direct experience on the efficacy, safety, tolerability, accessibility, and adherence of specific drugs.
Using Drug Ratings, SERMO’s community of global physicians has submitted more than three million data points, including ratings and comments on more than 2,100 pharmaceutical brands. In excess of 40,000 physicians have submitted ratings, and more than 60,000 have used the platform to search for ratings from their peers. The database now holds over 35,000 unique comments on physicians’ opinions on both new and established pharmaceuticals.
Statistics support the importance of peer influence in medicine. A poll of more than 2,900 SERMO physicians found that 83 percent reported that the opinion or feedback of a fellow physician has changed their perception of a drug. Further, 80 percent trust recommendations of a very large number of doctors with real-world experience with a drug, over the recommendations of a small number of key opinion leaders and academics. 1 Underscoring physicians’ trust in the system, 84 percent believe Drug Ratings will lead to better patient outcomes.2
“When it comes to finding information about prescription drugs, doctors are often limited to what’s provided by the manufacturer. In my experience, that does not capture the full picture of how patients experience drugs—including possible adverse effects, how much they pay out of pocket, and how well they work in the real world. Drug Ratings offers us the perspective and experience of our peers—which complements the information we get from product monographs and clinical trials,” said Dr. Len Antiles, a U.S. urologist.
1 SERMO poll of 2,918 doctors from Argentina, Austria, Australia, Canada, Switzerland, Chile, China, Colombia, Germany, Spain, Finland, France, Great Britain, Greece, Hungary, Ireland, Israel, India, Italy, Sri Lanka, Mexico, the Netherlands, Norway, New Zealand, Poland, Sweden, the United States, Venezuela and South Africa. It was fielded in April 2017. The margin of error is ± 2%.
2 SERMO poll of 2,017 doctors from the U.S., Italy, the U.K., France, Canada, Brazil, Belgium, Poland, Sweden, Korea, Switzerland, Colombia, Israel, Japan, and South Africa. It was fielded in October 2017. The margin of error for this poll is ±2%.